Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin.
Affiliation
Department of Nephrology, Beaumont Hospital, Dublin, Ireland.Issue Date
2010-11MeSH
AgedAnti-Bacterial Agents
Arthritis, Infectious
Drug Interactions
Drug Therapy, Combination
Follow-Up Studies
Fusidic Acid
Heptanoic Acids
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Male
Middle Aged
Osteomyelitis
Pyrroles
Rhabdomyolysis
Severity of Illness Index
Metadata
Show full item recordCitation
Severe rhabdomyolysis as a consequence of the interaction of fusidic acid and atorvastatin. 2010, 56 (5):e11-5 Am. J. Kidney Dis.Journal
American journal of kidney diseases : the official journal of the National Kidney FoundationDOI
10.1053/j.ajkd.2010.07.011PubMed ID
20888103Abstract
Rhabdomyolysis is a known complication of statin therapy and may be triggered by a pharmacokinetic interaction between a statin and a second medication. Fatal statin-induced rhabdomyolysis has an incidence of 0.15 deaths/million prescriptions. We describe 4 cases of severe rhabdomyolysis with the common feature of atorvastatin use and coadministration of fusidic acid. All cases involved long-term therapy with atorvastatin; fusidic acid was introduced for treatment of osteomyelitis or septic arthritis. Three cases occurred in the setting of diabetes mellitus, with 2 in patients with end-stage renal disease, suggesting increased susceptibility to atorvastatin-fusidic acid-induced rhabdomyolysis in these patient populations. Of the 4 patients in this series, 3 died. Fusidic acid is a unique bacteriostatic antimicrobial agent with principal antistaphylococcal activity. There have been isolated reports of rhabdomyolysis attributed to the interaction of statins and fusidic acid, the cause of which is unclear. Fusidic acid does not inhibit the cytochrome P450 3A4 isoenzyme responsible for atorvastatin metabolism; increased atorvastatin levels due to inhibition of the glucuronidation pathway may be responsible. Considering the low frequency of fusidic acid use, the appearance of 4 such cases within a short time and in a small population suggests the probability that development of this potentially fatal complication may be relatively high.Item Type
ArticleLanguage
enISSN
1523-6838ae974a485f413a2113503eed53cd6c53
10.1053/j.ajkd.2010.07.011
Scopus Count
Collections
Related articles
- Rhabdomyolysis with atorvastatin and fusidic acid.
- Authors: O'Mahony C, Campbell VL, Al-Khayatt MS, Brull DJ
- Issue date: 2008 Jun
- Rhabdomyolysis following co-prescription of fusidic acid and atorvastatin.
- Authors: Teckchandani S, Robertson S, Almond A, Donaldson K, Isles C
- Issue date: 2010 Mar
- [Rhabdomyolysis following the coprescription of atorvastatin and fusidic acid].
- Authors: Gabignon C, Zeller V, Le Guyader N, Desplaces N, Lidove O, Ziza JM
- Issue date: 2013 Jan
- Severe statin-induced rhabdomyolysis mimicking Guillain-Barré syndrome in four patients with diabetes mellitus treated with fusidic acid.
- Authors: Collidge TA, Razvi S, Nolan C, Whittle M, Stirling C, Russell AJ, Mann AC, Deighan CJ
- Issue date: 2010 Jun
- Acute rhabdomyolysis after atorvastatin and fusidic acid therapy.
- Authors: Wenisch C, Krause R, Fladerer P, El Menjawi I, Pohanka E
- Issue date: 2000 Jul